Source comparison
MK-677 Protocol Comparison: Dosage, Timing, and Monitoring
10mg Before bed, empty stomach 160-200 ng/mL Low (2-5% fasting glucose rise) Sleep quality, mild GH support Initial titration, insulin-sensitive women, combination with HRT 12.5mg 180-220 ng/mL Moderate (5-10% fasting glucose rise) Balanced lean mass + sleep s
This comparison does not assign a generated winner or score.
- 10mg
- Before bed, empty stomach
- 160-200 ng/mL
- Low (2-5% fasting glucose rise)
- Sleep quality, mild GH support
- Initial titration, insulin-sensitive women, combination with HRT
- 12.5mg
- 180-220 ng/mL
- Moderate (5-10% fasting glucose rise)
- Balanced lean mass + sleep support
- Maintenance dose for most perimenopausal women
- 15mg
- 200-240 ng/mL
- Moderate (8-12% fasting glucose rise)
- Lean mass retention, body recomposition focus
- Active training women, good glucose tolerance baseline
- 20mg
- 220-280 ng/mL
- Higher (12-18% fasting glucose rise)
- Maximum anabolic response, collagen synthesis
- Short-term recomposition phases (12-16 weeks), excellent metabolic health only
- 25mg+
- 250-320 ng/mL
- Significant (15-25% fasting glucose rise)
- Not recommended for perimenopausal women
- Avoid. Insulin resistance risk outweighs benefit in this population